Lite Strategy (LITS) Common Equity (2011 - 2026)
Lite Strategy (LITS) posted Common Equity of $56.8 million for Q1 2026, down 30.56% on a QoQ basis from $81.8 million in Q4 2025, and up 190.86% year-over-year from $19.5 million in Q1 2025.
Analysis
Lite Strategy (LITS) Common Equity (2011 - 2026) Analysis & Trends
Lite Strategy has reported Common Equity for 16 years, with the latest figure at $56.8 million in Q1 2026.
- On a quarterly basis, Common Equity rose 190.86% year-over-year to $56.8 million in Q1 2026; TTM through Mar 2026 was $56.8 million, a 190.86% increase from a year earlier, with the FY2025 full-year figure at $16.9 million, down 48.73% from the prior year.
- Common Equity was $56.8 million for Q1 2026 at Lite Strategy, down from $81.8 million in the prior quarter.
- The five-year high for Common Equity was $112.3 million in Q3 2025, with the low at $16.9 million in Q2 2025.
- Average Common Equity over 5 years is $48.5 million, with a median of $48.4 million recorded in 2022.
- The sharpest annual moves came in 2024 and 2025: Common Equity plunged 69.42% in 2024, then jumped 351.28% in 2025.
- Over 5 years, Common Equity stood at $48.4 million in 2022, then grew by 22.98% to $59.5 million in 2023, then sank by 62.85% to $22.1 million in 2024, then jumped by 270.4% to $81.8 million in 2025, then slumped by 30.56% to $56.8 million in 2026.
- The last three Common Equity figures came in at $56.8 million (Q1 2026), $81.8 million (Q4 2025), and $112.3 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 4.92 Bn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | 56.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 56.84 Mn |
| Dec 31, 2025 | 81.85 Mn |
| Sep 30, 2025 | 112.27 Mn |
| Jun 30, 2025 | 16.93 Mn |
| Mar 31, 2025 | 19.54 Mn |
| Dec 31, 2024 | 22.10 Mn |
| Sep 30, 2024 | 24.88 Mn |
| Jun 30, 2024 | 33.02 Mn |
| Mar 31, 2024 | 51.03 Mn |
| Dec 31, 2023 | 59.49 Mn |
| Sep 30, 2023 | 81.36 Mn |
| Jun 30, 2023 | 24.62 Mn |
| Mar 31, 2023 | 34.35 Mn |
| Dec 31, 2022 | 48.37 Mn |
| Sep 30, 2022 | 37.31 Mn |
| Jun 30, 2022 | 52.41 Mn |
| Mar 31, 2022 | 67.81 Mn |
| Dec 31, 2021 | 73.33 Mn |
| Sep 30, 2021 | 34.30 Mn |
| Jun 30, 2021 | 49.47 Mn |